Limitations, agreements, and source contact

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas · Source last updated 2022-08-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

limitations And Caveats

description

Due to lower accrual (N=1), there was insufficient data available in order to meet the primary and secondary outcome measures.

point Of Contact

email

ram9116@med.cornell.edu

organization

Weill Cornell Medicine

phone

212-746-6575

title

Rajiv Magge

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice